The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.

Veradermics' oral VDPHL01 shows first efficacy data in women, boosting hair count 22.7 hairs/cm² at 6 months; Phase 2/3 trial due 2027.

The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female…